Systematic Reviews
Copyright ©The Author(s) 2024.
World J Crit Care Med. Mar 9, 2024; 13(1): 89026
Published online Mar 9, 2024. doi: 10.5492/wjccm.v13.i1.89026
Table 2 Summary of consensus statements
Number
Summary of consensus statements
1There is the need for adjuvant therapy (CytoSorb® haemoadsorption) in the management of refractory septic shock patients, when the standard of care is insufficient
2In refractory septic shock cycle, CytoSorb® ideally be initiated within a maximum of 24 h after diagnosis and start of standard therapy
3In the initiation of CytoSorb® therapy in refractory septic shock patient, IL-6 levels are not a pre-requisite or mandatory parameter for decision making
4In a subset of patients, more than one CytoSorb® adsorber may be required to achieve sufficient haemodynamic stabilization
5In continuation of CytoSorb® therapy, the absorber should be changed after 6-24 h depending on the clinical course and the machine type availability
6CytoSorb® therapy is generally a safe therapy
7Sepsis-induced AKI requiring RRT is not a prerequisite to initiate CytoSorb® therapy in refractory septic shock patients
8The evaluation of the efficacy of CytoSorb® therapy should be based on endpoints like haemodynamic stabilization, inflammatory biomarkers, and/or improvement in the organ function, instead of mortality
9The (displayed, Figure 2) flowchart can be helpful to a doctor very new to the therapy to ensure a certain level of best practice